Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration

Distribution of vaccines which require refrigerated or frozen storage can be challenging and expensive. The adenovirus vector platform has been widely used for COVID-19 vaccines while several further candidate vaccines using the platform are in clinical development. In current liquid formulations, a...

Bibliografske podrobnosti
Main Authors:	Zhang, C, Berg, A, Joe, C, Dalby, PA, Douglas, A
Format:	Journal article
Jezik:	English
Izdano:	Springer Nature 2023

Podobne knjige/članki

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
od: Cheng Zhang, et al.
Izdano: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
od: Adam Berg, et al.
Izdano: (2021-10-01)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
od: Charlotte Davis, et al.
Izdano: (2024-06-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
od: Hermosilla, E, et al.
Izdano: (2022)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
od: Folegatti, P, et al.
Izdano: (2019)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
od: Eduardo Hermosilla, et al.
Izdano: (2022-03-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
od: Pedro M. Folegatti, et al.
Izdano: (2019-05-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
od: Moreira Folegatti, P
Izdano: (2021)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
od: Bas de Laat, et al.
Izdano: (2022-07-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
od: Rujittika Mungmunpuntipantip, et al.
Izdano: (2021-11-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
od: Simone Barocci, et al.
Izdano: (2022-03-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
od: Ogbe, A, et al.
Izdano: (2022)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
od: Giorgio Berlot, et al.
Izdano: (2022-01-01)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
od: Lea Krutzke, et al.
Izdano: (2022-07-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
od: Tamara Garibashvili, et al.
Izdano: (2022-06-01)

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
od: Jennifer Serwanga, et al.
Izdano: (2024-01-01)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
od: Jinnam Kim, et al.
Izdano: (2023-04-01)

ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
od: Loes H. Willems, et al.
Izdano: (2021-12-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
od: Ane Ogbe, et al.
Izdano: (2022-04-01)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
od: Antrobus, R, et al.
Izdano: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
od: Antrobus, R, et al.
Izdano: (2014)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
od: Manabendra Basu, et al.
Izdano: (2024-01-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
od: Gerardo Casucci, et al.
Izdano: (2021-06-01)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
od: Marek Mikołajczyk, et al.
Izdano: (2022-12-01)

Arterial thrombosis following first-dose ChAdOx1 vaccination: a case series
od: Christopher Ward, et al.
Izdano: (2022-05-01)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
od: Md. Altamash Ahmad, et al.
Izdano: (2023-03-01)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
od: Larissa Henze, et al.
Izdano: (2023-01-01)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
od: Salma Al Bahrani, et al.
Izdano: (2021-09-01)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
od: Zoltán Bánki, et al.
Izdano: (2022-06-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
od: López-Camacho, C, et al.
Izdano: (2020)

Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues
od: Anita Badbaran, et al.
Izdano: (2021-12-01)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
od: Edmund G.-T. Wee, et al.
Izdano: (2024-08-01)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
od: Wang-Huei Sheng, et al.
Izdano: (2022-04-01)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
od: César López-Camacho, et al.
Izdano: (2020-06-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
od: Dicks, M, et al.
Izdano: (2015)

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - author's reply
od: Voysey, M, et al.
Izdano: (2021)

Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
od: Leimapokpam Sumitra Devi, et al.
Izdano: (2022-01-01)

Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
od: Ekachai Singhatiraj, et al.
Izdano: (2021-09-01)

Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination
od: Caterina Francesca Bagella, et al.
Izdano: (2021-12-01)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
od: Jer-Hwa Chang, et al.
Izdano: (2022-02-01)